Abstract
e12647 Background: low-molecular-weight heparin (LMWH) treatment was recommended by international guidelines for a period of 3-6 months in patients with cancer-associated thromboembolism. The aims ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
